VYM vs XBI
Vanguard High Dividend Yield ETF vs SPDR S&P Biotech ETF
- • VYM has the lower expense ratio at 0.04% vs 0.35% for XBI.
- • VYM pays a higher dividend yield (2.24%).
Side-by-side metrics
| Metric | VYM | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.04% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.24% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $100.99B | $10.92B |
YTD return | 15.40% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.64 | 1.01 |
P/E ratio | 20.64 | — |
Last price | $164.98 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VYM top holdings
| AVGO | Broadcom Inc | 6.93% |
| JPM | JPMorgan Chase & Co | 3.75% |
| XOM | ExxonMobil Holdings Corp | 2.84% |
| JNJ | Johnson & Johnson | 2.71% |
| ABBV | AbbVie Inc | 1.96% |
| CSCO | Cisco Systems Inc | 1.80% |
| CVX | Chevron Corp | 1.61% |
| CAT | Caterpillar Inc | 1.56% |
| MRK | Merck & Co Inc | 1.52% |
| BAC | Bank of America Corp | 1.50% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VYM
VYM (Vanguard High Dividend Yield ETF) is US large-caps with above-average dividend yields. Managed by Vanguard, the fund carries $101.0B in assets under management, an expense ratio of 0.04%, a dividend yield of 2.24%. Its largest holding is Broadcom Inc (AVGO), which represents 6.9% of the portfolio. Real Estate is the fund's largest sector exposure at 0.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.